India's second biggest vaccines company
Bharat Biotech International Limited, a biotechnology company, engages in the research, development, and manufacture of vaccines and biotherapeutics. Its products include Revac-B+, a recombinant hepatitis-B vaccine; TYPBAR, a vi polysaccharide typhoid vaccine; BIOPOLIO, a poliomyelitis vaccine; INDIRAB, a rabies vaccine; Revac-Bmcf, a thiomersal free recombinant hepatitis-B vaccine; TEVAC, a tetanus vaccine; Scorgen, a scorpion venom anti-serum; and BioHib, a haemophilus influenza type b vaccine
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 3, 2020 | Grant | $14.10M | 1 | Coalition for Epidemic Preparedness Innovations | — | Detail |
Jan 1, 2019 | Series Unknown | — | 1 | Subhkam Ventures | — | Detail |
Dec 16, 2016 | Private Equity(PE) | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Coalition for Epidemic Preparedness Innovations | Yes | Grant |
Subhkam Ventures | Yes | Series Unknown |
The Carlyle Group | — | Private Equity(PE) |
Bharat Biotech has acquired 1 organizations. Their most recent acquisition was Chiron Behring Vaccines on Feb 18, 2019. They acquired Chiron Behring Vaccines for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Feb 18, 2019
Chiron Behring Vaccines
|
Biotechnology | acquisition | — | Detail |